セッション詳細
[P2]Poster Session Core Time (偶数番号)
2026年3月3日(火) 18:20 〜 19:20
ポスター発表（大輪田ホワイエ）
[P2-2]Neuroendocrine–Immune Crosstalk:
A Pro-Inflammatory Potential of Rare Epithelial Cells
*Masahiro Nemoto1, Masahiro Kiuchi1, Kaori Tsuji1, Toshinori Nakayama1, Kiyoshi Hirahara1 (1. Department of Immunology, Chiba University Graduate School of Medicine (Japan))
[P2-4]Regnase-1-mediated regulation of neutrophils modulates SARS-CoV-2-induced pneumonia
*Keiko Yasuda1,2, Junichi Aoki1, Kotaro Tanaka1, Osamu Takeuchi1 (1. Department of Medical Chemistry, Graduate School of Medicine, Kyoto University (Japan), 2. Department of Immunology, Nagoya City University Graduate School of Medical Sciences (Japan))
[P2-6]Integrated single-cell and spatial transcriptomics reveals the function of expanded intratumoral B cell clones
*Tomomi Namiki1, Mikiya Takata1, Ayumu Tsubosaka1, Kyohei Sano1, Miwako Kakiuchi1, Daisuke Koumura1, Hiroto Katoh2, Tetsuo Ushiku3, Shumpei Ishikawa1 (1. Department of Preventive Medicine, Graduate School of Medicine, The University of Tokyo (Japan), 2. National Cancer Center Exploratory Oncology Research & Clinical Trial Center (Japan), 3. Department of Pathology, Graduate School of Medicine, The University of Tokyo, Division of Pathology (Japan))
[P2-8]Identification of bone marrow niche components supporting the longevity of antibody-secreting cells
*Takuya Koike1,2, Kenta Horie3, Yari Shinya4, Junichi Kikuta2,4, Wataru Ise2, Masaru Ishii2,4, Eiryo Kawakami3, Tomohiro Kurosaki2, Takeshi Inoue1,2 (1. The UTOPIA Center, The University of Tokyo (Japan), 2. IFReC, The University of Osaka (Japan), 3. Graduate School of Medicine, Chiba University (Japan), 4. Graduate School of Medicine and Frontier Biosciences, The University of Osaka (Japan))
[P2-10]SLE合併DLBCL症例におけるCAR-T療法後の自己抗体とウイルス関連抗体の解析：症例報告
Differential Immune Recovery of Autoantibodies and Virus-associated Antibodies After CAR-T Cell Therapy for DLBCL in a Patient with SLE: A Case Report
*Kazuki Matsukawa1, Yasuhiro Kato1, Kazuhiro Sanda2, Atsuko Tsujii1, Akihisa Hino2, Yumiko Mizuno1, Tomoaki Ueda2, Naoki Hosen2, Atsushi Kumanogoh1 (1. Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka (Japan), 2. Department of Hematology and Oncology, Graduate School of Medicine, The University of Osaka (Japan))
[P2-12]Immune responses induced by seasonal coronavirus infection do not affect severe pneumonia caused by SARS-CoV-2 infection in cynomolgus macaques
*Oahida Akter1, Hirohito Ishigaki1, Yasushi ITOH1 (1. Division of pathogenesis and disease regulation, Department of Pathology,Shiga University of Medical Science (Japan))
[P2-14]Recirculating Tissue-Imprinted CD4+ Memory T Cells Drive Cross-Tissue Inflammation
*Chiaki Iwamura1,2, Rui Hirasawa2, Masahiro Kiuchi2, Kiyoshi Hirahara1,2 (1. cSIMVa, Chiba University (Japan), 2. Department of Immunology, Graduate School of Medicine, Chiba University (Japan))
[P2-16]Development of a Highly Sensitive Neutralizing Antibody Assay in Mucosal Samples from Mice, Non-human Primates, and Humans for Nasal COVID-19 Vaccine Research
*Meito Shibuya1,2,3, Seiki Shirai1,2,3, Morio Nagira1,2,3, Takahito Ito3, Mina Yamamoto2,3, Hiroshi Kiyono1,2,4,5,6,7, Kotaro Fujihashi1,2,7,8,9 (1. Department of Human Mucosal Vaccinology, Chiba University Hospital, Chiba (Japan), 2. Synergy Institute for Futuristic Mucosal Vaccine Research and Development (cSIMVa), Chiba University, Chiba (Japan), 3. Vaccine R&D Laboratory, Vaccine Business Division, Shionogi & Co., Ltd. (Japan), 4. Future Medicine Education and Research Organization, Chiba University, Chiba (Japan), 5. Department of Medicine, UC San Diego School of Medicine, San Diego, CA (USA), 6. CU-UCSD Center for Mucosal Immunology, Allergy and Vaccines (cMAV), UC San Diego School of Medicine, San Diego, CA (USA), 7. Division of Infectious Disease Vaccine R&D, Research Institute of Disaster Medicine, Chiba University, Chiba (Japan), 8. Division of Mucosal Vaccines, International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo (Japan), 9. Department of Pediatric Dentistry, The University of Alabama at Birmingham, Birmingham AL (USA))
[P2-18]Hypoxia reprogram transient immunosuppression in tissue resident Th2 cells under chronic inflammatory conditions
*Atsushi Sasaki1,2,3, Masahiro Kiuchi1, Hiroyuki Yagyu1, Toshinori Nakayama4, Takuji Suzuki2,3, Kiyoshi Hirahara1,3 (1. Department of Immunology, Graduate School of Medicine, Chiba University (Japan), 2. Department of Respirology, Graduate School of Medicine, Chiba University (Japan), 3. Chiba University, Synergy Institute for Futuristic Mucosal Vaccine Research and Development (Japan), 4. Chiba University (Japan))
[P2-20]ゲムシタビンと WT1₁₂₆ ペプチドワクチンの併用療法を受けた膵癌患者からの新規高アビディティ TCR の単離
Isolation of a novel high-avidity TCR in pancreatic cancer patients treated with the combination of gemcitabine and WT1126 peptide vaccine
*Soyoko Morimoto1,3, Sumiyuki Nishida2,3, Fumihiro Fujiki4, Atsushi Kumanogoh2,3, Haruo Sugiyama5 (1. Department of Cancer Stem Cell Biology, Graduate School of Medicine, The University of Osaka (Japan), 2. Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka (Japan), 3. Center for Advanced Modalities and Drug Delivery System, The University of Osaka (Japan), 4. Department of Cancer Immunotherapy, Graduate School of Medicine, The University of Osaka (Japan), 5. Department of Cancer Immunology, Graduate School of Medicine, The University of Osaka (Japan))
[P2-22]Mechanism and strategy of monoclonal cross-species reactive IgA treatment for gut microbiota regulation
*Genta Furuya1, Fumihito Usui2, Keishu Takahashi1, Satoru Nagatoishi3, Rae Maeda4, Tomoki Yoshihara5, Ryutaro Tamano1, Tomoya Ohno1, Kengo Sasaki1, Naoki Morita1, Peng Gao1, Fabian Eisenstein6, Hirofumi Kosuge3, Masumi Shirakawa7, Hiroyuki Arai8, Min Fey Chek5, Radostin Danev6, Hirotada Mori9, Masahide Kikkawa6, Shinsuke Sando7, Naoshi Dohmae10, Toshio Hakoshima5, Yuki Sugiura4, Kouhei Tsumoto3, Reiko Shinkura1 (1. Institute for Quantitative Biosciences, The University of Tokyo (Japan), 2. Applied Immunology, Graduate School of Science and Technology, Nara Institute of Science and Technology (Japan), 3. Department of Bioengineering, School of Engineering, The University of Tokyo (Japan), 4. Center for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicine (Japan), 5. Division of Biological Science, Graduate School of Science and Technology, Nara Institute of Science and Technology (Japan), 6. Graduate School of Medicine, The University of Tokyo (Japan), 7. Department of Chemistry and Biotechnology, Graduate School of Engineering, The University of Tokyo (Japan), 8. Department of Biotechnology, Graduate School of Agricultural and Life Sciences, The University of Tokyo (Japan), 9. Faculty of Engineering, Shinshu University (Japan), 10. Biomolecular Characterization Unit, RIKEN Center for Sustainable Resource Science (Japan))
[P2-24]Sox4 in Treg Cells Suppresses IL-10 Production via c-Maf Degradation and Exacerbates Type 2 Inflammation
*Yuki Hayashi1, Kensuke Suga1, Akira Suto1, Arifumi Iwata1, Junichi Ishikawa1, Kazuya Abe1, Takahiro Kageyama1, Takashi Ito1,2, Shigeru Tanaka1, Kotaro Suzuki1, Masakatsu Yamashita3, Veronique Lefebvre4, Hiroshi Nakajima1,2 (1. Department of Allergy and Clinical Immunology, Chiba University (Japan), 2. Chiba University Synergy Institute for Futuristic Mucosal Vaccine Research and Development (cSIMVa), Chiba University (Japan), 3. Department of Immunology, Ehime University (Japan), 4. Department of Surgery, Division of Orthopaedic Surgery, Children’s Hospital of Philadelphia, Pennsylvania (USA))
[P2-26]新規記憶B細胞サブセットは saRNAワクチン接種者おける抗体価の持続性を予測する
Novel memory B cell subset predicts durability of antibody response to self-amplifying RNA vaccines in humans
*Taishi Onodera1, Saya Moriyama1, Takuto Nogimori3, Ayae Nishiyama3, Takuya Yamamoto3, Wataru Akahata2, Yoshimasa Takahashi1 (1. Research Center for Vaccine Development. National Institute of Infectious Deseases, Japanese Institute for health security (Japan), 2. VLP Therapeutics Japan Inc. (Japan), 3. National Institutes of Biomedical Innovation, Health and Nutrition Center for Intractable Diseases and Immuno Genomica (Japan))
[P2-28]Seasonal Influenza Vaccination Modifies Host Cytokine Responses
*Yutaka Muto1, Kohei Tsujimoto1, Reo Shiratani1, Shintaro Shichinohe2, Tokiko Watanabe2, Atsushi Kumanogo1, Sumiyuki Nishida1 (1. Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka (Japan), 2. Department of Molecular Virology, Research Institute for Microbial Diseases, The University of Osaka (Japan))
[P2-30]Physiological gastric acid exposure regulates esophageal mucosal immune homeostasis via Ccl2-producing macrophages
*Akane Kurosugi1, Chiaki Iwamura1, Kohei Kakinuma1, Kiyoshi Hirahara1 (1. Department of Immunology, Graduate School of Medicine, Chiba University (Japan))
[P2-34]Mapping the Human Intrahepatic CD4+ T Cell Landscape and Its Contribution to Antiviral Defense Against Cytomegalovirus
*Hajime Morita1, Lynn Zreka1, Ma Shuhe1,3, Toshiaki Bando1, Mouna Khan1, Yuki Masuo1, Shunsuke Uno1, Hirotaka Sato1, Joey Mashuyama1, Ryo Nishida1, Wajid Amin1, Shinya Okumura2, Etsuro Hatano2, Takashi Ito2, Hironori Haga5, Hideki Ueno1,3,4 (1. Department of Immunology, Kyoto University (Japan), 2. Division of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Kyoto University (Japan), 3. ASHBi Institute for the Advanced Study of Human Biology, Kyoto University (Japan), 4. Kyoto University Immunomonitoring Center (KIC), Kyoto University (Japan), 5. Department of Diagnostic Pathology, Kyoto University (Japan))
[P2-36]ワクチン開発に向けた汎動物学アプローチ：子牛におけるワクチン誘導性T細胞応答の増強
A Zoobiquity approach for vaccine development: Enhancement of vaccine-induced T-cell responses in calves
*Naoya Maekawa1,2, Mari Ikehata1, Tomohiro Okagawa1, Shiro Murata1,3, Kazuhiko Ohashi1,3,4, Satoru Konnai1,2,3 (1. Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University (Japan), 2. Institute for Vaccine Research and Development, Hokkaido University (Japan), 3. Veterinary Research Unit, International Institute for Zoonosis Control, Hokkaido University (Japan), 4. International Affairs Office, Faculty of Veterinary Medicine, Hokkaido University (Japan))
[P2-38]リソソームDNAストレスは、TLR9を介した肝線維化を誘導する
Lysosomal DNA stress triggers TLR9-mediated emergency myelopoiesis and Liver fibrosis
*Ryota Sato1, Takuma Shibata2, Kiyoshi Yamaguchi3, Yoichi Furukawa3, Kenta Nakano4, Tadashi Okamura4, Ryutaro Fukui1, Yuji Motoi1, Kensuke Miyake1 (1. Synergy Institute for Futuristic Mucosal Vaccine Research and Development (Japan), 2. Nishimura Lab, The Institute of Medical Science, The University of Tokyo (Japan), 3. Division of Clinical Genome Research, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo (Japan), 4. Department of Laboratory Animal Medicine, Japan Institute for Health Security (Japan))
[P2-40]腸管組織炎症におけるGPR41の機能解析
Functional analysis of GPR41 in intestinal tissue inflammation.
*Takashi Ito1,2, Ayako Tomikawa2, Hiroshi Nakajima1,2 (1. Synergy Institute for Futuristic Mucosal Vaccine Research and Development, Chiba University. (Japan), 2. Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan (Japan))
[P2-42]TLR7機能獲得変異は、リガンドに対する応答性を高め、かつリガンド特異性を緩和することでヒトループスを発症させる
TLR7 variants enhance responsiveness and broaden RNA specificity to drive human lupus
*Asuka Takayama1, Kazuyuki Meguro1,2, Takuma Shibata3, Kensuke Miyake2, Hiroshi Nakajima1,2 (1. Department of Allergy and Clinical Immunology, Chiba University (Japan), 2. Chiba University Synergy Institute for Futuristic Mucosal Vaccine Research and Development (cSIMVa), Chiba University, (Japan), 3. Division of Aging and Regeneration, The Institute of Medical Science, The University of Tokyo (Japan))
[P2-44]CD69 regulates agonist TCR signaling
*Yukihiro Endo1, Nanako Yasujima1, Motoko Kimura1 (1. Department of Experimental Immunology, Graduate School of Medicine, Chiba University (Japan))
[P2-46]Comprehensive profiling of Human liver γδ T cells reveals CMV-driven immune remodeling
*Mouna Khan1, Hajime Morita1, Toshiaki Bando1, Lynn Zreka1, Shuhe Ma1,3, Daichi Akuzawa, Yuki Masuo1, Shunsuke Uno1, Hirotaka Sato1, Joey Matsuyama1, Ryo Nishida1, Shinya Okumura2, Etsuro Hatano2, Takashi Ito2, Hiroyuki Yoshitomi1,3,4, Hideki Ueno1,3,4 (1. Immunology and cell biology laboratory, Graduate school of medicine, Kyoto university (Japan), 2. Division of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan. (Japan), 3. ASHBi Institute for the Advanced Study of Human Biology, Kyoto University, Kyoto, Japan. (Japan), 4. Kyoto University Immuno-monitoring Center (KIC), Kyoto University, Kyoto, Japan. (Japan))
[P2-48]温度依存的な SARS-CoV-2 の複製
Temperature-dependent SARS-CoV-2 replication
*Takeshi Ichinohe1 (1. Institute of Medical Science, The University of Tokyo (Japan))
[P2-50]Improving rotavirus-based vaccine vectors by identifying novel foreign gene insertion sites
*Takahiro Kawagishi1, Kanako Matsumura1, Shizuka Sonoda1, Katsuhisa Hirai1, Shohei Minami1, Tomohiro Kotaki1, Yuta Kanai1, Takeshi Kobayashi1,2,3 (1. Research Institute for Microbial Diseases, The University of Osaka (Japan), 2. Center for Advanced Modalities and DDS, The University of Osaka (Japan), 3. Center for Infectious Disease Education and Research, The University of Osaka (Japan))
[P2-52]Investigating the factors influencing exercerbation of disease after coinfection with influenza virus and SARS-CoV-2 and the protective role of co-vaccination
*Chimuka Handabile1,2, Marumi Ohno1,2, Toshiki Sekiya1,2,3, Yuichi Koshiishi2, Tomomi Kawakita1,2,4, Richard Obeng-Kyeremh2, Yasushi Itoh5, Naoki Nomura2, Michihito Sasaki6, Toshihiro Ito1,2, Masashi Shingai1,2,4, Hiroshi Kida1,2 (1. Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan (Japan), 2. Division of Biologics Development, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan (Japan), 3. The Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia (Australia), 4. Division of Vaccine Immunology, Hokkaido University International Institute for Zoonosis Control, Sapporo, Japan (Japan), 5. Department of Pathology, Shiga University of Medical Science, Otsu, Japan (Japan), 6. Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan (Japan))
[P2-54]変異株に対する交差反応性向上を目的とした構造情報に基づく受容体結合ドメインを閉じたSARS-CoV-2スパイク蛋白質の設計および評価
Structure-guided design of receptor-binding domain-down SARS-CoV-2 spike protein to enhance cross-reactivity against variants
*Takuya Hemmi1,2, Saya Moriyama3, Akira Ainai2, Hisano Yajima1, Rin Shirota1, Tomo Nomai4, Shunsuke Kita4, Satoru Nagatoishi5, Kouhei Tsumoto5, Yukihiko Sugita6, Takeshi Noda6, Katsumi Maenaka4, Yoshimasa Takahashi3, Tadaki Suzuki2,7, Takao Hashiguchi1,8 (1. Laboratory of Medical virology, Institute for Life and Medical Sciences, Kyoto University (Japan), 2. Department of Infectious Disease Pathology, National Institute of Infectious Diseases, Japan Institute for Health Security (Japan), 3. Research Center for Vaccine Development, National Institute of Infectious Diseases, Japan Institute for Health Security (Japan), 4. Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University (Japan), 5. Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, Tokyo (Japan), 6. Laboratory of Ultrastructural Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto (Japan), 7. Department of Infectious Disease Pathobiology, Graduate School of Medicine, Chiba University (Japan), 8. Kyoto University Immunomonitoring Center, Kyoto University (Japan))
[P2-56]Phylogenetic analysis and pathogenicity assessment of high pathogenicity avian influenza viruses isolated from crows in Sapporo, Hokkaido
*Kazuki Nishikawa1, Norikazu Isoda1,2,3,4, Yik Lim Hew1, Daiki Kobayashi1, Yo Shimazu1, Fumihito Takaya5, Takahiro Hiono1,2,3,4, Yoshihiro Sakoda1,2,3,4 (1. Laboratory of Microbiology, Faculty of Veterinary Medicine, Hokkaido University (Japan), 2. One Health Research Center (OHRC), Hokkaido University (Japan), 3. International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University (Japan), 4. Institute for Vaccine Research and Development (IVReD), Hokkaido University (Japan), 5. Field Science Center for Northern Biosphere, Hokkaido University (Japan))
[P2-58]How Does Fasting Affect Vaccine Effectiveness?
*Ryuta Uraki1, Yoshihiro Kawaoka1 (1. The UTOPIA Center, The University of Tokyo (Japan))
[P2-60]キャップ依存性エンドヌクレアーゼ阻害剤はラクロスウイルス感染に対して抗ウイルス薬として作用する
A cap-dependent endonuclease inhibitor acts as a potent antiviral agent against La Crosse virus infection
*Kei Konishi1,2,3, Yoshiyuki Taoda4, Manabu Igarashi3, Takao Shishido2, Kazuya Yasuo4, Yasuko Orba1,3, Hirofumi Sawa1,5, Michihito Sasaki1,3, Akihiko Sato1,2,3 (1. Institute for Vaccine Research and Development, Hokkaido University (Japan), 2. Laboratory for Drug Discovery & Disease Research, Shionogi & Co., Ltd. (Japan), 3. International Institute for Zoonosis Control, Hokkaido University (Japan), 4. Laboratory for Medicinal Chemistry Research, Shionogi & Co., Ltd. (Japan), 5. One Health Research Center, Hokkaido University (Japan))
[P2-62]オルプーシェウイルスのNSsは宿主のRNAポリメラーゼIIを分解することで、宿主遺伝子発現を抑制する
Nucleolar targeting by Oropouche virus NSs mediates RNA polymerase II degradation and interferon antagonism
*Rokusuke Yoshikawa1,2, Jiro Yasuda1,2 (1. Institute of Tropical Medicine (NEKKEN), Nagasaki University (Japan), 2. National Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University (Japan))
[P2-64]インフルエンザウイルスのHAストーク領域の変異体の網羅的解析
Comprehensive analysis of mutants in the influenza virus HA stalk domain
*Shinji Saito1, Yasushi Suzuki2, Osamu Kotani3, Akira Ainai4, Tabata Koshiro1, Yukari Itakura1, Gabriel Gonzalez1, Hideki Hasegawa2, Hirofumi Sawa1 (1. Institute for Vaccine Research and Development: HU-IVReD, Hokkaido University (Japan), 2. Research Center for Influenza and Respiratory Viruses, National institute of infectious diseases, Japan Institute for Health Security (Japan), 3. Pathogen Genomics Center, National Institute of Infectious Diseases, Japan Institute for Health Security (Japan), 4. Department of Infectious Disease Pathology, National Institute of Infectious Diseases, Japan Institute for Health Security (Japan))
[P2-66]B6系統マウスに馴化したSARS-CoV-2を用いたブレイクスルー感染モデルの構築
Adaptation of SARS-CoV-2 to C57BL/6 mice and its application in breakthrough infection models.
*Takasuke Fukuhara1 (1. Faculty of Medical Sciences, Kyushu University (Japan))
[P2-68]NSs遺伝子を改変した組換えバンダウイルスのバンダウイルスワクチンとしての評価
Evaluation of NSs gene-modified recombinant bandaviruses as bandavirus vaccines
*Satoshi Taniguchi1,2, Shigeru Tajima2, Ken-Ichi Shibasaki2, Masayuki Saijo2, Masayuki Shimojima2, Chang-Kweng Lim2, Misao Himeno1, Hideki Ebihara2 (1. Graduate school of Medicine, The University of Tokyo (Japan), 2. Department of Virology I, National Institute of Infectious Diseases, Japan Institute for Health Security (Japan))
[P2-70]Establishment of a CRISPR Knockout Mouse Library and In Vivo Screening System for Functional Analysis of Influenza Virus Host Factors
*Hiroshi Ueki1,2,3, Yuriko Tomita3,4, Calvin Duong3, Hiromichi Mitake3, Maki Kiso1,3, Yuri Furusawa2,3,5, Dongming Zhao3, Tiago Jose da Silva Lopes3,6,7, Li Wu3, Huapeng Feng3, Seiya Yamayoshi1,2,3, Satoshi Fukuyama3, Makoto Yamashita3, Manabu Ozawa8, Masahito Ikawa8,9, Nobuaki Yoshida10, Tokiko Watanabe3,11,12,13, Yoshihiro Kawaoka1,2,3,6 (1. The University of Tokyo, Pandemic Preparedness, Infection and Advanced Research Center (Japan), 2. International Virus Infectious Disease Research Center, National Institute of Global Health and Medicine, Japan Institute for Health Security (JIHS) (Japan), 3. Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo (Japan), 4. Influenza Research Center, National Institute of Infectious Diseases, Japan Institute of Health and Security (JIHS) (Japan), 5. Laboratory for Immunotherapy, RIKEN Center for Integrative Medical Sciences (Japan), 6. Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison (USA), 7. Nezu Biotech GmbH (Germany), 8. Laboratory of Reproductive Systems Biology, Center for Experimental Medicine and Systems Biology, Institute of Medical Science, The University of Tokyo (Japan), 9. Department of Experimental Genome Research, Research Institute for Microbial Diseases, Osaka University (Japan), 10. Laboratory of Developmental Genetics, Center for Experimental Medicine and Systems Biology, The University of Tokyo (Japan), 11. Department of Molecular Virology, Research Institute for Microbial Diseases, The University of Osaka (Japan), 12. Center for Infectious Disease Education and Research (CiDER), The University of Osaka (Japan), 13. Center for Advanced Modalities and DDS (CAMaD), The University of Osaka (Japan))
[P2-72]2023年－2024年のケニア共和国マンデラ郡におけるヒトコブラクダおよびヒトにおける中東呼吸器症候群ウイルス感染症の検出
Detection of Active Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection in Dromedary Camels and Camel Herders in Mandera County, Kenya, 2023-2024
Abdiaziz Ali1, Sora Guyo1, Abdulsalam Swaleh Karama1, Elizabeth Ajema Chebichi Luvai2,3, Allan Biwott ole Kwallah2,4, Japheth katana5, Hassan Mohamed Aburo6, Ali Noor6, *Shingo Inoue2 (1. Mandera Branch, KEMRI (Kenya), 2. Kenya Research Station, Institute of Tropical Medicine, Nagasaki University (Japan), 3. Technical University of Kenya (Kenya), 4. CCR, KEMRI (Kenya), 5. CMR. KEMRI (Kenya), 6. Mandera County Veterinary Office (Kenya))
[P2-74](EK)₄KK修飾LNPは細胞との相互作用を高め、条件依存的にmRNA発現特性に影響を与える
(EK)4 KK-Modified LNPs Enhance Cell-Nanoparticle Interactions and Influence mRNA Expression Profiles in a Condition-Dependent Manner
*Chiemi Matsuguchi1, Makoto Matsumoto2, Haruki Shimada2, Yura Kobayashi1, Hanano Fukii1, Hidefumi Mukai2, Shigeru Kawakami2 (1. Pharmaceutical Sciences Nagasaki University (Japan), 2. Nagasaki University Graduate School of Biomedical Sciences (Japan))
[P2-76]ELUCIDATING THE MECHANISMS UNDERLYING RECOMBINANT BCG-INDUCED CROSS-PROTECTION AGAINST VIRAL INFECTIONS
*Gabriel Talaia1,2, Patrick Kao1,2, Koichi Kobayashi1,2,3 (1. Department of Immunology, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido (Japan), 2. Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Hokkaido (Japan), 3. Department of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, Bryan, Texas (USA))
[P2-78]AI-Guided Rational Design of Next-Generation Dengue Fever Vaccine
*Sebastian Kapell2,1, Shara Bakytbek4,9, Farzaneh Valanezhad4,9, Mya Myat Ngwe Tun9,10, Jean Claude Balingit10, Ayako Hyuga4,9, Shin-Ichi Inoue9,6, Yui Katsuyuki9,6, Shusaku Mizukami5,9, Shinjiro Hamano4,9, Matheus Ferraz2, Ioannis Vardaxis2, Daiki Mori3, Daiki Miura3, Kazuhide Onoguchi3, Kaidre Bendjama2,1, Basu Dev Pandey8, Corazon Cerilla Buerano10, Trevor Clancy2, Haruka Abe9,11, Satoshi Kaneko9,7, Kouichi Morita10,9 (1. Department of Vaccine Informatics, Institute of Tropical Medicine, Nagasaki University (Japan), 2. NEC Oncoimmunity AS (Norway), 3. NEC Corporation (Japan), 4. Department of Parasitology, Institute of Tropical Medicine, Nagasaki University (Japan), 5. Department of Immune Regulation, SHIONOGI global infectious diseases division (SHINE), Institute of Tropical Medicine (NEKKEN), Nagasaki University (Japan), 6. Department of Immunology, Graduate School of Biomedicine, Nagasaki University (Japan), 7. Department of Eco-Epidemiology, Institute of Tropical Medicine, Nagasaki University (Japan), 8. Department of Molecular Epidemiology, Institute of Tropical Medicine, Nagasaki University (Japan), 9. Vaccine Research and Development Center Infectious Disease Research Alliance (DEJIMA), Nagasaki University (Japan), 10. Department of Tropical Viral Vaccine Development, Institute of Tropical Medicine, Nagasaki University (Japan), 11. Vietnam Research Station, NEKKEN, Nagasaki University (Japan))
[P2-80]Library Vaccine Antigen as a Novel Approach to Rapidly Evolving Pathogens
*Shiho Chiba1,2, Maki Kiso1,3, Yoshihiro Kawaoka1,2,3,4 (1. The UTOPIA Center, The University of Tokyo (Japan), 2. University of Wisconsin-Madison (USA), 3. Institute of Medical Science, the University of Tokyo (Japan), 4. The Research Center for Global Viral Diseases, National Institute of Global Health and Medicine, Japan Institute for Health Security (Japan))
[P2-82]Computationally guided T-cell vaccine design for protection against invasive non-typhoidal Salmonella (iNTS)
Sebastian Kapell1,4, *Eugen Bauer1, Sarunporn Tandhavanant5, Agnieszka Gromadka1, Anja Moesch2,4, Daiki Mori3, Kazuhide Onoguchi3, Kaïdre Bendjama1,4, Toshio Kodama5 (1. NEC Oncoimmunity AS (Norway), 2. NEC Laboratories Europe (Germany), 3. NEC Corporation (Japan), 4. Department of Vaccine Informatics, Institute of Tropical Medicine, Nagasaki University (Japan), 5. Department of Bacteriology, Institute of Tropical Medicine, Nagasaki University (Japan))
[P2-84]免疫活性化を増強するHFQ脂質修飾による樹状細胞由来細胞外小胞 DEVOTE‑HFQ脂質の開発
Enhanced Immune Activation by DEVOTE-HFQ: Dendritic Cell-Derived Extracellular Vesicles Optimized via Tailored Engineering Using HFQ Lipid
*Makoto Matsumoto1, Yoshimasa Tanaka1, Masayuki Kaneko1, Koji Matsuhisa1, Shigeru Kawakami1 (1. Nagasaki University Graduate School of Biomedical Sciences (Japan))
[P2-86]筋注後の局所発現最適化と炎症誘発低減を実現するmRNA-LNP技術
mRNA-LNP Technology Enabling Optimized Local Expression and Reduced Inflammation Induction after Intramuscular Injection
*Yusuke Ushiroda2, Makoto Matsumoto1, Kazuya Okami1, Shintaro Fumoto1,2, Riku Takayama2, Akari Kiguchi2, Hidefumi Mukai1,2, Shigeru Kawakami1,2 (1. Nagasaki University Graduate School of Biomedical Sciences (Japan), 2. Nagasaki University Pharmaceutical sciences (Japan))
[P2-88]T-Cell Immunogenicity of AI-Predicted Malaria Vaccine Elements Assessed by IFN-γ Enzyme-Linked Immunospot Assay
*Shara Bakytbek1,2,3, Agnieszka Gromadka4, Wataru Kagaya3,5, Huai Chuang3,6, Yarob Ibraheem1,2,3, Farzaneh Valanezhad1,2,3, Ayako Hyuga1,2,3, Marius Gheorghe4, Daiki Miura7, Alexandru Odainic4, Shin-Ichi Inoue2,8, Shusaku Mizukami3,9, Satoshi Kaneko3,5, Kazuhide Onoguchi7, Sebastian Kapell4,10, Kaidre Bendjama4, Osamu Kaneko3,6, Shinjiro Hamano1,2,3 (1. Department of Parasitology, Institute of Tropical Medicine (NEKKEN), The Joint Usage/Research Center on Tropical Disease, Nagasaki University, Nagasaki (Japan), 2. Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki (Japan), 3. The Vaccine Research and Development Center, DEJIMA Infectious Disease Research Alliance (DIDA), Nagasaki University, Nagasaki (Japan), 4. NEC Oncoimmunity AS, Oslo (Norway), 5. Department of Eco-epidemiology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki (Japan), 6. Department of Protozoology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki (Japan), 7. AI Drug Development Division, NEC Corporation, Tokyo (Japan), 8. Department of Molecular Microbiology and Immunology, Division of Immunology, Nagasaki University, Nagasaki (Japan), 9. Department of Immune Regulations, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki (Japan), 10. Department of Vaccine Informatics, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki (Japan))
[P2-90]効果的な免疫誘導を目指した新規AAVベクターワクチンの構築と有効性検証
Construction and evaluation of novel AAV vector vaccines aimed at effective immune induction
*Ken Sugo1, Hiroshi Ueki2,3,4, Yuji Tsunekawa1, Emiko Urano5, Yukage Kobari1, Yasunari Matsuzaka1, Koji Kobiyama6, Guillermo Posadas-Herrera1, Hiromi Hayashita-Kinoh1, Mikako Wada1, Yukihiko Hirai1, Yasushi Soda1, Yasuhiro Yasutomi5, Ken J. Ishii6,7,8,9,10, Seiya Yamayoshi2,3,4, Yoshihiro Kawaoka2,3,4, Takashi Okada1 (1. Division of Molecular and Medical Genetics, Center for Gene and Cell Therapy, The Institute of Medical Science, The University of Tokyo (Japan), 2. Division of Virology, The Institute of Medical Science, The University of Tokyo (Japan), 3. Center for Global Viral Diseases, National Institute of Global Health and Medicine (Japan), 4. The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA) (Japan), 5. Laboratory of Immunoregulation and Vaccine Research, Tsukuba Primate Research Center, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) (Japan), 6. Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo (Japan), 7. Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo (Japan), 8. Graduate School of Medicine and Faculty of Medicine, The University of Tokyo (Japan), 9. International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo (Japan), 10. Laboratory of Vaccine Science, Immunology Frontier Research Center, The University of Osaka (Japan))
[P2-92]ニードルフリー表皮内投与デバイスを用いた
次世代型モックアップワクチンの開発
Development of a next-generation mock-up vaccine using an intraepidermal needle-free vaccination device
*Keiichi Motoyama1,2, Masahiro Ogura2, Riru Onigahara2, Shunsuke Sasaki3, Naoki Kishimoto1,3, Shogo Msisumi1,3, Toru Taharabaru1,2, Taishi Higashi1,2, Hirotoshi Adachi4, Masahiko Kikuchi1,5 (1. Vaccine Development Research Center, Kumamoto University (Japan), 2. Graduate School of Pharmaceutical Sciences, Kumamoto University (Japan), 3. Department of Environmental and Molecular Health Sciences, Kumamoto University (Japan), 4. PassPort Technologies, Inc (USA), 5. The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (Japan))
[P2-94]Expression and chromatin accessibility quantitative trait loci uncover genetic regulation and immune mechanisms in finely sorted 29 immune cell types
*Hiroki Kitaoka1,2, Rintaro Fujimoto1,2,3, Saya Hisano1,3, Akiko Oguchi1,4, Raku Son1,4, Ryuya Edahiro1,3, Go Sato1,3, Yoshihiko Tomofuji1,2, Matteo Maurizio Guerrini1, Yasuhiro Murakawa1,4, Akari Suzuki1, Yukinori Okada1,2,3, Kazuhiko Yamamoto1 (1. RIKEN Integrative Medical Sciences (Japan), 2. The University of Tokyo (Japan), 3. The University of Osaka (Japan), 4. Kyoto University (Japan))
[P2-96]Multi-layered single-cell genomics deconvolutes biological mechanisms underlying clonal hematopoiesis and mitochondrial heteroplasmyin infectious & autoimmune diseases
*Go Sato1,2,3, Ryuya Edahiro2,3, Tomohiro Yata2, Kotaro Ogawa2, Tatsuhiko Naito1,2, Kyuto Sonehara1,2,3, Ryunosuke Saiki4, Shinichi Namba1,2,3, Yuya Shirai2,3, Kenichi Yamamoto2, Seishi Ogawa4, Hideki Mochizuki2, Noriko Isobe5, Tatsusada Okuno2, Atsushi Kumanogoh2, Yukinori Okada1,2,3 (1. Graduate School of Medicine, the University of Tokyo (Japan), 2. Graduate School of Medicine, the University of Osaka (Japan), 3. RIKEN Center for Integrative Medical Sciences (Japan), 4. Graduate School of Medicine, Kyoto University (Japan), 5. Graduate School of Medical Sciences, Kyusyu University (Japan))
[P2-98]Confidential
*Rintaro Fujimoto1,2,3, Kotaro Ogawa1, Shinichi Namba1,2,3, Yosuke Ogawa2, Ryuya Edahiro1,3, Kyuto Sonehara1,2, Shiori Tagawa2, Tomohiro Yata1, Yuya Shirai1, Yuji Yamamoto1, Go Sato1,2,3, Chifune Kai1, Tatsuhiko Naito1,2,3, Tatsusada Okuno1, Noriko Isobe4, Yukinori Okada1,2,3 (1. Department of Statistical Genetics, Osaka University Graduate School of Medicine (Japan), 2. The University of Tokyo (Japan), 3. Laboratory for Systems Genetics, RIKEN Center for Integrative Medical Sciences (Japan), 4. Kyushu University (Japan))
[P2-100]5′ single-cell mapping of transcribed enhancers reveals cell-type–specific regulatory changes in aging human skin
*Akiyoshi Senda1,2,3, Akiko Oguchi1,4,5, Raku Son1,4,5, Daisuke Akiyama1,2,6, Yasuhiro Murakawa1,2,4,7 (1. Institute for the Advanced Study of Human Biology, Kyoto University (Japan), 2. Department of Pathology and Biology of Diseases, Graduate School of Medicine, Kyoto University (Japan), 3. Department of Dermatology, Graduate School of Medicine, Kyoto University (Japan), 4. Laboratory for Gene Structure and Regulation, RIKEN Center for Integrative Medical Sciences (Japan), 5. Department of Nephrology, Graduate School of Medicine, Kyoto University (Japan), 6. Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University (Japan), 7. IFOM ETS - the AIRC Institute of Molecular Oncology (Italy))
[P2-102]A multi-scale map of protein assemblies in the DNA damage response
*Anton Kratz1 (1. DEJIMA Infectious Disease Research Alliance and The Institute of Tropical Medicine (NEKKEN), Nagasaki University (Japan))
[P2-104]Genetics of immune response in monocytes from Japanese healthy donors
*Matteo Guerrini1 (1. RIKEN IMS (Japan))
[P2-106]Sperm and offspring production in a nonobstructive azoospermia mouse model via testicular mRNA delivery using lipid nanoparticles
*Daisuke Mashiko1, Chihiro Emori1, Yuki Hatanaka1, Daisuke Motooka1, Chen Pan1, Yuki Kaneda1, Martin M Matzuk2, Masahito Ikawa1 (1. RIMD, The University of Osaka (Japan), 2. Center for Drug Discovery, Department of Pathology & Immunology, Baylor College of Medicine (USA))
[P2-108]組換えカニクイザル絨毛性性腺刺激ホルモンの樹立
Establishment of recombinant cynomolgus chorionic gonadotropin
*Toshifumi Morimura1, Nao Maeda1, Yuko Abiko1, Azusa Nakayama1, Masatsugu Ema1 (1. Research Center for Animal Life Science, Shiga University of Medical Science (Japan))
[P2-110]Generation and application of humanized mice with human pulmonary alveolar tissues using human induced pleuripotent stem cells in vivo.
*Takeshi Takahashi1, Akira Yamagata2,3, Satoshi Konishi2, Satoshi Ikeo3, Hiroshi Moriyama4, Senye Takahashi2, Naoyuki Sone2, Satoshi Hamada3,5, Atsushi Saito6, Takashi Kawaguchi7, Shu Hisata8, Akira Niwa2, Toshiaki Kikuchi9, Hirofumi Chiba6, Megumu K Saito2, Koichi Hagiwara8, Toyohiro Hirai3, Mio Iwasaki10, Takuya Yamamoto10,11,12, Shimpei Gotoh2 (1. Division of Multiverse Medical Sciences, CIEM (Japan), 2. Center for iPS Cell Research and Application (CiRA), Kyoto University (Japan), 3. Departmentn of Respiratory Medicine, Graduate School of Medicine, Kyoto University (Japan), 4. Respiratory Center, National Hospital Organization Nishiniigata Chuo Hospital (Japan), 5. Department of Advanced Medicine for Respiratory Failure, Graduate School of Medicine, Kyoto University (Japan), 6. Department of Respiratory Medicine and Allergoloty, Sapporo Medical University School of Medicine (Japan), 7. Kawaguchi Respiratory Clinic (Japan), 8. Division of Pulmonary Medicine, Department of Medicine, Jichi medical University (Japan), 9. Department of Respiratory Medicine and Infectious Diseases, Niigata Univerisity Graduate School of Medical and Dental Sciences (Japan), 10. Department of Life Science Frontiers, CiRA, Kyoto University (Japan), 11. Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University (Japan), 12. Medical-risk Avoidance Based on iPS cells team, RIKEN Center for Adcanced Intelligence Project (AIP) (Japan))
[P2-112]新規重症免疫不全糖尿病マウスモデルの開発
A Novel Immunodeficient Hyperglycemic Mouse Carrying the Ins1 Akita Mutation
Kenta Nakano1, Motohito Goto2, Riichi Takahashi2, *TADASHI OKAMURA1 (1. Japan Institute for Health Security (JIHS) (Japan), 2. Central Institute for Experimental Medicine and Life Science (CIEM) (Japan))
[P2-114]低起炎性に向けたmRNA-LNP製剤処方の開発
Development of mRNA–LNP Formulations with Reduced Inflammatory Properties
*Yusuke Sato1, Rikuto Taneda1, Mai Yakuwa1, Mina Sato1, Hideyoshi Harashima1 (1. Graduate School of Pharmaceutical Sciences, Hokkaido University (Japan))
[P2-116]URAは研究者の共創者：研究を支える支援事例と未来への展望
URA as a Co-Creator: Supporting Research through Case Studies and Future Perspectives
*Yuko Yamamoto1 (1. Chiba University, Synergy Institute for Futuristic Mucosal Vaccine Research and Development (Japan))
[P2-118]Structural biology approach to fight
infectious diseases
*Yoshiaki Kise1, Kanata Matsumoto1, Kazuhiro Sawada1, Hana Matsushita1, Shin Mukai1, Osamu Nureki1 (1. Department of Biological Sciences, The University of Tokyo (Japan))
[P2-120]ウイルスパンデミックを撲滅する構造・合成生物学アプローチ
Structural and synthetic biology approaches to combat viral pandemic
*Osamu Nureki1 (1. Graduate School of Science, The University of Tokyo (Japan))
[P2-122]Global Climate-Driven Malaria and Dengue Risk Mapping Using Deep Learning Transformers Under Present and Future Warming Scenarios
*Micheal Teron Pillay1, Mai Le Thi Quynh 2, Yuki Takamatsu1, Tran Vu Phong2, Ratnam Jayanthi3, Kyoko Futami1, Satoshi Kaneko1, Noboru Minakawa1 (1. Institute of Tropical Medicine, Nagasaki University (Japan), 2. National Institute of Hygiene and Epidemiology (Viet Nam), 3. Japan Agency for Marine-Earth Science and Technology (Japan))
[P2-124]Developing a machine learning model to find consistent patterns in unsupervised multimodal omics data
*Dorothy DeMore Ellis1, Jun Seita1 (1. RIKEN IMS (Japan))
[P2-126]麻しん・風しんワクチンの抗体持続に及ぼすワクチン株の役割：外来残余検体と母子手帳を用いた小児集団解析
Impact of Vaccine Strains on the Persistence of Measles and Rubella Antibodies in a Pediatric Population Using Residual Clinical Samples and Maternal and Child Health Handbook
*Munehiro Furuichi1,2, Yoshifumi Uwamino1,3,4, Kazuma Yagi1,3,4, Masayoshi Shinjoh1,2, Ho Namkoong1,3,4 (1. Division of Infectious Diseases and Infection Control, Keio University Hospital (Japan), 2. Department of Pediatrics, Keio University School of Medicine (Japan), 3. Department of Infectious Diseases, Keio University School of Medicine (Japan), 4. Clinical Infectious Diseases Center, Keio University Hospital (Japan))
[P2-128]COVID-19 mRNAワクチンブースター接種後の長期自然減衰
Long-term Natural Waning of Humoral Immunity After COVID-19 mRNA Vaccine Booster Doses
*Yoshifumi Uwamino1, Kengo Nagashima2, Ho Namkoong1 (1. Keio University School of Medicine (Japan), 2. Keio University Hospital (Japan))
[P2-130]ネクストパンデミックに備える呼吸器感染症の包括的研究基盤としてのEDCシステム構築
Building an EDC System as a Comprehensive Research Infrastructure for Respiratory Infectious Diseases in Preparation for the Next Pandemic
*Kazuma Yagi1, Takeshi Arashiro1, Takanori Asakura1, Munehiro Furuichi1, Yoshifumi Uwamino1, Ho Namkoong1 (1. Keio University School of Medicine (Japan))
[P2-132]新生児における腸管防御因子の候補としてのGlycoprotein2の同定
Identification of Glycoprotein 2 as an Intestinal Defense Factor in Neonates
*NAREN TONGLEGA1,2, Zhongwei Zhang1,2, Sayuri Murasaki1,2, Fujimi Arai1,2,3, Tamami Matsushita1,2, Yosuke Kurashima1,2,3,4,5 (1. Department of Innovative Medicine, Graduate School of Medicine, Institute for Advanced Academic Research/ Research Institute of Disaster Medicine, Chiba University, Chiba (Japan), 2. Institute for Advanced Academic Research/ Research Institute of Disaster Medicine, Chiba University, Chiba, (Japan), 3. Chiba University Synergy Institute for Futuristic Mucosal Vaccine Research and Development (cSIMVa), Department of Human Mucosal Vaccinology, Chiba University Hospital, (Japan), 4. Chiba University-University of California San Diego Center for Mucosal Immunology, Allergy and Vaccine (CU-UCSD cMAV), Department of Medicine, School of Medicine, San Diego, CA, USA. (USA), 5. Synergy Institute for Futuristic Mucosal Vaccine Research and Development, Chiba University, Chiba, (Japan))
[P2-134]Trypanosoma cruziの細胞内寄生期に対する殺原虫化合物の優先順位付けのための革新的なアッセイ系の開発
High-throughput rate-of-kill assay, an innovative approach for prioritization of trypanocidal compounds against Trypanosoma cruzi amastigote stage
Mizuki Hayashishita1,2,3, Michele Lika Furuya1,2, Japheth Kibet Ng’etich4,5,6, Jean-Robert Ioset7, Takeshi Nara8, Takaya Sakura1,2,9, *Daniel Ken Inaoka1,2,9,10 (1. School of Tropical Medicine and Global Health, Nagasaki University (Japan), 2. Department of Infection Biochemistry, Institute of Tropical Medicine (NEKKEN), Nagasaki University (Japan), 3. Brazil Research Station, National Research Center for the Control and Prevention of Infectious Diseases (CCPID), Nagasaki University (Japan), 4. Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University (Japan), 5. Program for Nurturing Global Leaders in Tropical and Emerging Communicable Diseases, Graduate School of Biomedical Sciences, Nagasaki University (Japan), 6. Center for Traditional Medicine and Drug Research, Kenya Medical Research Institute (Kenya), 7. Drugs for Neglected Diseases Initiative (Switzerland), 8. Laboratory of Molecular Parasitology, Graduate School of Life Science and Technology, Iryo Sosei University (Japan), 9. Department of Molecular Infection Dynamics, Institute of Tropical Medicine (NEKKEN), Nagasaki University (Japan), 10. Department of Biomedical Chemistry, Graduate School of Medicine, The University of Tokyo (Japan))
[P2-136]HIV陽性者を包摂する非HIV感染症に対するワクチン開発とワクチン接種の課題に関する文献レビュー
Literature Review on Challenges in Development and Administration of Vaccines Against Non-HIV Infections that Include HIV-Positive Individuals
*Miku Shimasaki1, Kyoko Mimura2, Chihiro Nishi2, Izen Ri2, Kaori Muto2,3 (1. Graduate School of Frontier Sciences, The University of Tokyo (Japan), 2. The Institute of Medical Science, The University of Tokyo (Japan), 3. Center for Integrative Medical Sciences, RIKEN (Japan))
[P2-138]Building a Regional Primary Human Airway Epithelial Resource for Mucociliary Clearance Assays and Organoid Host-Response Studies
*Takanori Asakura1, Yu Shionoya2,4, Takuya Ozawa1, Shuhei Azekawa1, Rima Kanai1, Tomoya Tamaki1, Makoto Ishii3, Ho Namkoong4, Koichi Fukunaga1 (1. Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan (Japan), 2. Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan. (Japan), 3. Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Japan (Japan), 4. Department of Infectious Disease, Keio University School of Medicine, Japan (Japan))
[P2-140]マイケルアクセプター含有合成アルカロイドは宿主POLE3への共有結合を介してB型肝炎ウイルス複製を抑制する
Michael acceptor-containing programmed synthetic alkaloid covalently binds host POLE3 and inhibits HBV replication
*Misao Himeno1,2, Nobuto Kaneko3, Yuhi Kobayashi3, Ryo Tanifuji3, Hiroki Kubota4, Haruki Mizoguchi5, Makoto Muroi6, Takehiro Suzuki6, Masaya Sugiyama7, Naoshi Dohmae6, Hiroyuki Osada6, Taketomo Kido2, Atsushi Miyajima2, Hiroki Oguri3 (1. Department of Developmental Medical Sciences, The University of Tokyo (Japan), 2. Laboratory of Cell Growth and Differentiation, Institute for Quantitative Biosciences, The University of Tokyo (Japan), 3. Department of Chemistry, Graduate School of Science, The University of Tokyo (Japan), 4. Department of Applied Chemistry, Graduate School of Engineering, Tokyo University of Agriculture and Technology (Japan), 5. Graduate School of Natural Science and Technology, Okayama University (Japan), 6. Centre for Sustainable Resource Science, RIKEN (Japan), 7. Department of Viral Pathogenesis and Control, National Institute of Global Health and Medicine (Japan))
[P2-142]効率的な臨床研究推進に向けた次世代PBMC採取装置の開発
Development of a Next-Generation PBMC Collection System for Efficient Clinical Research
*Hiromitsu Tazawa1, Osamu Kikuchi1,2, Yuki Furuya1, Yuko Matsuura1, Miki Ohkita1, Kazuhiro Nakamura4, Osamu Segawa4, Kazumi Sawakami4, Hideji Tajima4, Manabu Muto1,3 (1. . Clinical Bio-Resource Center, Kyoto University Hospital (Japan), 2. Center for Cancer Immunotherapy and Immunobiology, Kyoto University (Japan), 3. Ckinical Oncology, Kyoto University Hospital (Japan), 4. Precision System Science Inc. & Universal Bio Research Inc. (Japan))
[P2-144]Efficient recombinant protein–secretion platform for developing vaccines and diagnostics against mycobacterial diseases
*Hiroto Takeuchi1,2, Satoru Mizuno2, Kazuhiro Matsuo2 (1. International Institute for Zoonosis Control (Japan), 2. Institute for Vaccine Research and Development (Japan))